Navigation Links
Trubion Announces Presentations at Upcoming Investor Conferences
Date:3/5/2008

SEATTLE, March 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that executives will present an overview of the company at two March investor conferences:

-- March 10: Sanford Bernstein Biotechnology Conference in Alta, Utah. Dr.

Peter Thompson, president, CEO and chairman, will present to attendees.

-- March 18: Invest Northwest CEO & Investor Forum at the Bell Harbor

International Conference Center, 2211 Alaskan Way, Pier 66 in Seattle,

Wash. Dr. Ken Mohler, co-founder and senior vice president of Research

and Development, is scheduled to present at 11:20 a.m. PDT. The

presentation will be available via audio webcast at

http://www.wsw.com/webcast/in6/trbn/.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIPtm, therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.

Trubion's proprietary product candidat
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Martek Announces First Quarter 2008 Financial Results
2. HealthFitness Announces 2007 Fourth Quarter and Full-Year Results
3. Relax The Back Announces Record Growth in 2007; Executives Bullish on Specialty Retailers Prospects for 2008
4. AHRQ Announces New Members to U.S. Preventive Services Task Force
5. ADAMS Announces the Addition of Dani Barfield to the Firms Staff as Associate Project Manager
6. Trevena, Inc. Announces $24 Million Series A Financing
7. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
8. eDiets.com(R) Announces Q4 and Year End 2007 Results
9. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
10. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
11. Smith & Nephew Announces Breakthrough VERILAST(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)... New York Fashion Week,s Annual Destination to ...York, New York (PRWEB) September 5, 2008 -- http...__title__ American Laser], the largest provider of...c services in the U.S., announces sponsorship of t...YLE360, from Sept. 7-10, serves as the alternative...
(Date:9/4/2008)...ember 5, 2008Private Medicare Advantage (MA) plans...ollee in 2008 compared to what the same enrollee w...-service program, according to a new report from T...ons to MA plans mandated by the Medicare Improveme... scheduled to take effect beginning in 2010 had ...
(Date:9/4/2008)...ce of instructions they say could help doctors eva...hDay News) -- Vaccine safety experts say that almo...ve vaccinations with close monitoring and a set of...ember issue of Pediatrics , a team of experts led...a step-by-step set of instructions -- an algorithm...
(Date:9/4/2008)... Medelis, an oncology contract research organiz...nical Trials: A Nuanced Approach to Get Into the C...arry, a preclinical research scientist with 35 yea...al studies are commonly viewed as straightforward ...operate without true integration with preclinical,...
Breaking Medicine News(10 mins):Health News:American Laser Centers Sponsors STYLE360 to Share the Skinny on Body Shaping 2Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3
...irst time in 90 years the timings for the last ord... 11PM to round the clock drinking. Thousands of re...th an extra drink in pubs and bars after midnight.... reported. The relaxed opening hours, already a fe...
...s with whooping cough/Pertussis have tripled in Id...ople to get themselves revaccinated against infect... reported totally by central district health depar...) and Valley counties in southwest Idaho. Statisti...
...itted of a rape charge as he was suffering from Pa...tim and is going to have her case against him in C...ve sex // with a woman after a party when they wer...fa. Jan Luedecke argued that he was not aware or ...
...m: A recent funded survey indicates that the agein... rate in country eats// three meals a day and most...men and women over 60 years in Kerala eat three me...urvey’, funded by the Shastri Indo-Canadian Instit...
Other Medicine News:Health News:Three meals daily Keeps 'Kerala's elderly Healthy 2
(Date:9/4/2008)... Data for Ipilimumab to be Presented, PRINCETON, ...nc.,(Nasdaq: MEDX ) announced today that nine cli... anti-CTLA-4 antibody, in melanoma are scheduled t...ress of the European Society,for Medical Oncology ...lm.,Many of the following abstracts will include u...
(Date:9/4/2008)... on Schedule with Two Abstracts Accepted for P...vember 2008, BRIDGEWATER, N.J., Sept. 4 /PRNewswi... pharmaceutical company focused on the treatment o...unced the appointment of,Peter L. Garrambone, Jr. ...mbone,s career includes more than 50 pharmaceutica...
(Date:9/3/2008).../- Simcere,Pharmaceutical G...plier of,branded generic pharmaceuticals and manuf...t Endu (also known as Endostar) in China,announce...udy., At the request of the SFDA, Simcere initiat...he safety and therapeutic efficacy of Endu, a modi...
(Date:9/3/2008)...onal Vascular Disease Awareness Month, CHARLOTTES...maceuticals,LLC, a clinical-stage drug-development...nt of unmet medical needs, announced today that it...ical trial of its lead drug,candidate trans sodium...881,on the clinicaltrials.gov Website, is investig...
Breaking Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory 8672 1Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory 8672 2Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory 8672 3How to Survive an Unexpected Trip to the Hospital During Christmas and New Years 8668 1How to Survive an Unexpected Trip to the Hospital During Christmas and New Years 8668 2Indevus Comments on Bayer Healthcare Discontinuation of Viadur 28R 29 2352 1Indevus Comments on Bayer Healthcare Discontinuation of Viadur 28R 29 2352 2Indevus Comments on Bayer Healthcare Discontinuation of Viadur 28R 29 2352 3VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2348 1VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2348 2VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2348 3VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2348 4
...rstCall/ -- CEL-SCI,CORPORATION announces that CEL...an influenza antigen in combination with MAS-1, a,...ngs were,presented on May 23, 2007 by Dr. Daniel Z...lar Immunology at CEL-SCI at the,American Society ...,Toronto, Canada. , This new finding with CEL-1000...
...tCall/ -- Shire plc,announced today that DAYTRANA(...ntion Deficit Hyperactivity Disorder (ADHD) patch,... of ADHD in both,male and female children aged 6 t...ported at the American Psychiatric Association,(AP...udies have examined gender differences in the,resp...
Other Medicine Technology:CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response,Against Avian Flu Antigen in Animals 2Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 2Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 3Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 4Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 5Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 6Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 7Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls 8
This set offers the full range of Keeler magnifiers and telescopes.
This set is designed to introduce the low vision practitioner to the Keeler telescopic system.
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut
Featuring up to 20 tilting tower illumination allows examination in the vertical, horizontal and oblique sections plus the option to offset the slit for corneal transillumination., ,Filters inclu
Medicine Products: